Coated cross-species antibodies by mannosamine-biotin adduct confer protection against snake venom without eliciting humoral immune response

Tal Gefen; Jacob Pitcovski; Jacob Vaya; Soliman Khatib; Simi Krispel; E. Dan Heller; Elena Gaberman; Raphael Gorodetsky; Elina Aizenshtein

doi:10.1016/j.vaccine.2010.09.032

Coated cross-species antibodies by mannosamine-biotin adduct confer protection against snake venom without eliciting humoral immune response

Tal Gefen
, Jacob Pitcovski
, Jacob Vaya
, Soliman Khatib
, Simi Krispel
, E. Dan Heller
, Elena Gaberman
, Raphael Gorodetsky
, Elina Aizenshtein^*

^*Corresponding author for this work

Department of Animal Sciences

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Passive immunization with cross-species antibodies triggers the patient's immune response, thereby preventing repeated treatment. Mannosamine-biotin adduct (MBA) has been described as a masking agent for immunogenic reduction and here, the immunogenicity and biological activity of MBA-coated horse anti-viper venom (hsIgG) were compared to those of uncoated or PEGylated hsIgG. In in vitro tests, hsIgG binding was not affected by MBA conjugation. The immune response to hsIgG-MBA was about 8-fold and 32-fold lower than to PEG-coated and uncoated hsIgG, respectively. In vivo, hsIgG-MBA showed efficient venom-neutralization activity. We thus demonstrate the feasibility of using MBA as a masking agent for passive immunization with cross-species antibodies.

Original language	English
Pages (from-to)	8197-8202
Number of pages	6
Journal	Vaccine
Volume	28
Issue number	51
DOIs	https://doi.org/10.1016/j.vaccine.2010.09.032
State	Published - 29 Nov 2010

Keywords

Antigenicity reduction
Coated antibody
Mannosamine-biotin adduct
Passive vaccination
Snake venom

Access to Document

10.1016/j.vaccine.2010.09.032

Cite this

@article{2ea70cea5e834407be08ee17ac79a472,

title = "Coated cross-species antibodies by mannosamine-biotin adduct confer protection against snake venom without eliciting humoral immune response",

abstract = "Passive immunization with cross-species antibodies triggers the patient's immune response, thereby preventing repeated treatment. Mannosamine-biotin adduct (MBA) has been described as a masking agent for immunogenic reduction and here, the immunogenicity and biological activity of MBA-coated horse anti-viper venom (hsIgG) were compared to those of uncoated or PEGylated hsIgG. In in vitro tests, hsIgG binding was not affected by MBA conjugation. The immune response to hsIgG-MBA was about 8-fold and 32-fold lower than to PEG-coated and uncoated hsIgG, respectively. In vivo, hsIgG-MBA showed efficient venom-neutralization activity. We thus demonstrate the feasibility of using MBA as a masking agent for passive immunization with cross-species antibodies.",

keywords = "Antigenicity reduction, Coated antibody, Mannosamine-biotin adduct, Passive vaccination, Snake venom",

author = "Tal Gefen and Jacob Pitcovski and Jacob Vaya and Soliman Khatib and Simi Krispel and Heller, \{E. Dan\} and Elena Gaberman and Raphael Gorodetsky and Elina Aizenshtein",

year = "2010",

month = nov,

day = "29",

doi = "10.1016/j.vaccine.2010.09.032",

language = "אנגלית",

volume = "28",

pages = "8197--8202",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "51",

}

TY - JOUR

T1 - Coated cross-species antibodies by mannosamine-biotin adduct confer protection against snake venom without eliciting humoral immune response

AU - Gefen, Tal

AU - Pitcovski, Jacob

AU - Vaya, Jacob

AU - Khatib, Soliman

AU - Krispel, Simi

AU - Heller, E. Dan

AU - Gaberman, Elena

AU - Gorodetsky, Raphael

AU - Aizenshtein, Elina

PY - 2010/11/29

Y1 - 2010/11/29

N2 - Passive immunization with cross-species antibodies triggers the patient's immune response, thereby preventing repeated treatment. Mannosamine-biotin adduct (MBA) has been described as a masking agent for immunogenic reduction and here, the immunogenicity and biological activity of MBA-coated horse anti-viper venom (hsIgG) were compared to those of uncoated or PEGylated hsIgG. In in vitro tests, hsIgG binding was not affected by MBA conjugation. The immune response to hsIgG-MBA was about 8-fold and 32-fold lower than to PEG-coated and uncoated hsIgG, respectively. In vivo, hsIgG-MBA showed efficient venom-neutralization activity. We thus demonstrate the feasibility of using MBA as a masking agent for passive immunization with cross-species antibodies.

AB - Passive immunization with cross-species antibodies triggers the patient's immune response, thereby preventing repeated treatment. Mannosamine-biotin adduct (MBA) has been described as a masking agent for immunogenic reduction and here, the immunogenicity and biological activity of MBA-coated horse anti-viper venom (hsIgG) were compared to those of uncoated or PEGylated hsIgG. In in vitro tests, hsIgG binding was not affected by MBA conjugation. The immune response to hsIgG-MBA was about 8-fold and 32-fold lower than to PEG-coated and uncoated hsIgG, respectively. In vivo, hsIgG-MBA showed efficient venom-neutralization activity. We thus demonstrate the feasibility of using MBA as a masking agent for passive immunization with cross-species antibodies.

KW - Antigenicity reduction

KW - Coated antibody

KW - Mannosamine-biotin adduct

KW - Passive vaccination

KW - Snake venom

UR - https://www.scopus.com/pages/publications/78649647308

U2 - 10.1016/j.vaccine.2010.09.032

DO - 10.1016/j.vaccine.2010.09.032

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 20875497

AN - SCOPUS:78649647308

SN - 0264-410X

VL - 28

SP - 8197

EP - 8202

JO - Vaccine

JF - Vaccine

IS - 51

ER -

Coated cross-species antibodies by mannosamine-biotin adduct confer protection against snake venom without eliciting humoral immune response

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this